Products - Blood and bone marrow cancers | Topic

Showing 33 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood and bone marrow cancers Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 33 products

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491

Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249

Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477

Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949

Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991

Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437

Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468

Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478

Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376

Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493

Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121

Blood and bone marrow cancers Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 33 products

Status
1 selected